Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program
- PMID: 15604294
- DOI: 10.1158/0008-5472.CAN-04-2442
Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program
Abstract
Understanding the biology of prostate cancer metastasis has been limited by the lack of tissue for study. We studied the clinical data, distribution of prostate cancer involvement, morphology, immunophenotypes, and gene expression from 30 rapid autopsies of men who died of hormone-refractory prostate cancer. A tissue microarray was constructed and quantitatively evaluated for expression of prostate-specific antigen, androgen receptor, chromogranin, synaptophysin, MIB-1, and alpha-methylacylCoA-racemase markers. Hierarchical clustering of 16 rapid autopsy tumor samples was performed to evaluate the cDNA expression pattern associated with the morphology. Comparisons were made between patients as well as within the same patient. Metastatic hormone-refractory prostate cancer has a heterogeneous morphology, immunophenotype, and genotype, demonstrating that "metastatic disease" is a group of diseases even within the same patient. An appreciation of this heterogeneity is critical to evaluating diagnostic and prognostic biomarkers as well as to designing therapeutic targets for advanced disease.
Similar articles
-
Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles.Cancer Res. 2007 Jun 1;67(11):5117-25. doi: 10.1158/0008-5472.CAN-06-4040. Cancer Res. 2007. PMID: 17545589
-
Neuroendocrine expression in metastatic prostate cancer: evaluation of high throughput tissue microarrays to detect heterogeneous protein expression.Hum Pathol. 2000 Apr;31(4):406-14. doi: 10.1053/hp.2000.7295. Hum Pathol. 2000. PMID: 10821485
-
Chromogranin A expression in patients with hormone naïve prostate cancer predicts the development of hormone refractory disease.J Urol. 2007 Sep;178(3 Pt 1):838-43; quiz 1129. doi: 10.1016/j.juro.2007.05.018. Epub 2007 Jul 16. J Urol. 2007. PMID: 17631319
-
Discovery of prostate cancer biomarkers by microarray gene expression profiling.Expert Rev Mol Diagn. 2010 Jan;10(1):49-64. doi: 10.1586/erm.09.74. Expert Rev Mol Diagn. 2010. PMID: 20014922 Review.
-
Molecular regulation of androgen action in prostate cancer.J Cell Biochem. 2006 Oct 1;99(2):333-44. doi: 10.1002/jcb.20794. J Cell Biochem. 2006. PMID: 16518832 Review.
Cited by
-
GNAS codon 201 mutations are uncommon in intraductal papillary neoplasms of the bile duct.HPB (Oxford). 2012 Oct;14(10):677-83. doi: 10.1111/j.1477-2574.2012.00504.x. Epub 2012 Jun 18. HPB (Oxford). 2012. PMID: 22954004 Free PMC article.
-
Younger age is an independent predictor for poor survival in patients with signet ring prostate carcinoma.Prostate Cancer. 2011;2011:216169. doi: 10.1155/2011/216169. Epub 2010 Jul 20. Prostate Cancer. 2011. PMID: 22110982 Free PMC article.
-
Current uses and resistance mechanisms of enzalutamide in prostate cancer treatment.Expert Rev Anticancer Ther. 2024 Nov;24(11):1085-1100. doi: 10.1080/14737140.2024.2405103. Epub 2024 Sep 20. Expert Rev Anticancer Ther. 2024. PMID: 39275993 Review.
-
Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model.Neoplasia. 2007 Mar;9(3):200-6. doi: 10.1593/neo.07103. Neoplasia. 2007. PMID: 17401460 Free PMC article.
-
A phase 2 study of high-activity 186Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to bone.Eur J Nucl Med Mol Imaging. 2006 Sep;33(9):1055-61. doi: 10.1007/s00259-005-0010-5. Epub 2006 Mar 30. Eur J Nucl Med Mol Imaging. 2006. PMID: 16572306 Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical